NCT03184844 is a Phase 2 clinical trial of Thalidomide in Thalassemia, sponsored by Xiao-Lin Yin.

Who is sponsoring NCT03184844?

NCT03184844 is sponsored by Xiao-Lin Yin.

What drugs are being tested in NCT03184844?

Interventions in NCT03184844: Thalidomide.

What condition does NCT03184844 study?

NCT03184844 studies Thalassemia.

Is NCT03184844 still recruiting?

NCT03184844 is currently status unknown. Last updated 14 June 2017.

Last reviewed 2017-06-14 · How we verify

NCT03184844

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effective and Safety of Thalidomide in TI

Status unknown Phase 2 Last updated 14 June 2017

What this trial tests

Phase 2 trial testing Thalidomide in Thalassemia in 100 participants. Status unknown.

Timeline

2 May 2017

Primary endpoint
2 February 2019

2 May 2019

Quick facts

Lead sponsor	Xiao-Lin Yin
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	2 May 2017
Primary completion	2 February 2019
Estimated completion	2 May 2019
Sites	1 location across China

Drugs / interventions tested

Thalidomide (THALIDOMIDE) — full drug profile →

Conditions studied

Thalassemia — all drugs for Thalassemia →

Sponsor

Xiao-Lin Yin

Who can join

Adults 18 to 65, any sex, with Thalassemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an exploratory experiment, aims to explore the effective and safety of thalidomide in the treatment of TI to improve the hemoglobin level, improve the quality of life, reduce blood transfusion, so as to avoid the adverse reactions caused by transfusion,60\~100 patients will be enrolled.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia.
Ren Q, Zhou YL, Wang L, Chen YS, et al · · 2018 · cited 21× · PMID 29931453 · DOI 10.1007/s00277-018-3395-5

Verify or expand the search:

Other trials of Thalidomide

Trials testing the same drug.

NCT06772480 — Thalidomide Versus Argon Plasma Coagulation in Gastric Antral Vascular Ectasia(GAVE)-Related Anaemia in Cirrhosis (TAG T · NA · not yet recruiting
NCT06617182 — Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury. · Phase 2 · recruiting
NCT06382519 — Thalidomide Therapy for VEOIBD · recruiting
NCT06490627 — Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia · Phase 2 · recruiting
NCT06299670 — Efficacy of Combination of Hdroxyurea and Thalidomide Over Either Hydroxyurea or Thalidomide Alone in the Treatment of T · Phase 4 · unknown

Other recruiting trials for Thalassemia

Currently open trials in the same condition.

NCT06609226 — A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia · Phase 3 · recruiting
NCT07064941 — Effect of Exercise on Body Composition and Bone Health in Patients With Thalassemia · NA · recruiting
NCT06800495 — Development of THALEA Kit and Its Impact on Knowledge, Attitude, and Intention for Premarital Thalassemia Screening · NA · active not recruiting
NCT06313398 — Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling · EARLY_PHASE1 · recruiting
NCT05736419 — A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03184844 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xiao-Lin Yin
Last refreshed: 14 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03184844.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing